Explore 3 Stock Ideas & Industry Insights Download Free Report

18889881171
Shopping Cart 0
countryflagUS
Login

Avacta Group Plc

Healthcare US AVCTF

1.0USD
0.00(0%)

Last update at 2026-06-23T20:00:00Z

Day Range

1.001.00
LowHigh

52 Week Range

0.401.11
LowHigh

Fundamentals

  • Previous Close 1.00
  • Market Cap406.11M
  • Volume12000
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-29.40000M
  • Revenue TTM0.11M
  • Revenue Per Share TTM-
  • Gross Profit TTM 0.11M
  • Diluted EPS TTM-0.15

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2024-12-31 2023-12-31 2022-12-31 2022-07-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2024-12-31 2023-12-31 2022-12-31 2022-07-31 2021-12-31
Income before tax -28.98300M -26.47000M -41.64200M -41.64200M -29.19400M
Minority interest - - - - -
Net income -52.84100M -24.94700M -39.18900M -39.18900M -26.31600M
Selling general administrative 12.05M 2.91M 2.29M 2.29M 8.14M
Selling and marketing expenses 12.05M 16.86M 11.23M 11.23M 8.14M
Gross profit 0.11M 7.57M 7.24M 7.24M 2.02M
Reconciled depreciation 1.44M 3.67M 3.01M 3.01M 2.38M
Ebit -19.12900M -26.71700M -28.88100M -28.88100M -29.06600M
Ebitda -17.62400M -23.04600M -25.86900M -25.86900M -26.69000M
Depreciation and amortization 1.50M 3.67M 3.01M 3.01M 2.38M
Non operating income net other - - - - -
Operating income -32.55800M -26.71700M -32.64500M -32.64500M -29.08300M
Other operating expenses 32.67M 49.96M 37.47M 37.47M 32.02M
Interest expense 9.85M 14.73M 2.70M 2.70M 0.13M
Tax provision 0.44M -2.37000M -2.10200M -2.10200M -2.82000M
Interest income 0.66M 0.66M 0.09M 0.09M 0.02M
Net interest income -9.42800M -14.64300M -2.61000M -2.61000M -0.11100M
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense 0.44M -2.37000M -2.10200M -2.10200M -2.82000M
Total revenue 0.11M 23.25M 9.65M 9.65M 2.94M
Total operating expenses 32.67M 34.29M 35.06M 35.06M 31.10M
Cost of revenue 0.00000M 15.67M 2.41M 2.41M 0.92M
Total other income expense net 3.58M 0.25M -8.99700M -8.99700M -0.11100M
Discontinued operations - - - - 0.06M
Net income from continuing ops -29.42700M -24.94700M -39.54000M -39.54000M -26.37400M
Net income applicable to common shares - - - - -26.31600M
Preferred stock and other adjustments - - - - -
Breakdown 2024-12-31 2023-12-31 2022-12-31 2022-07-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2024-12-31 2023-12-31 2022-12-31 2022-07-31 2021-12-31
Total assets 48.27M 73.19M 92.65M 92.65M 47.00M
Intangible assets 0.30M 13.80M 12.09M 12.09M 6.39M
Earning assets - - - - -
Other current assets 27.32M 2.24M 1.76M - 3.75M
Total liab 38.99M 51.39M 74.21M 74.21M 5.78M
Total stockholder equity 9.28M 21.80M 18.44M 18.44M 41.22M
Deferred long term liab - - - - 6.05M
Other current liab 12.91M 7.92M -8.43100M 39.10M -3.64600M
Common stock 36.94M 28.50M 26.68M 26.68M 25.47M
Capital stock 36.94M 28.42M 26.68M 26.68M 25.39M
Retained earnings -138.82900M -85.75300M -65.99700M -65.99700M -34.09300M
Other liab - - - - -
Good will 1.54M 17.04M 14.23M 14.23M 1.54M
Other assets - - - - 6.05M
Cash 12.87M 16.63M 41.78M 41.78M 26.19M
Cash and equivalents - - - - -
Total current liabilities 37.30M 45.11M 67.61M 67.61M 4.37M
Current deferred revenue - 0.30M 38.23M 38.23M 0.05M
Net debt 10.06M 6.50M -17.93800M -17.93800M -24.48800M
Short term debt 21.45M 17.39M 20.09M 20.09M 0.29M
Short long term debt 20.50M 16.26M 18.73M 18.73M 0.00000M
Short long term debt total 22.93M 23.13M 23.84M 23.84M 1.70M
Other stockholder equity 111.17M 79.01M 57.75M 57.75M 49.84M
Property plant equipment - - - - 4.34M
Total current assets 40.20M 28.04M 55.55M 55.55M 34.74M
Long term investments - - - - -
Net tangible assets - - - - 39.34M
Short term investments - - - - -
Net receivables 0.00000M 8.82M 10.33M 5.58M 4.61M
Long term debt 0.00000M 0.22M 0.00000M - -
Inventory 0.00000M 2.58M 1.68M 1.68M 0.19M
Accounts payable 2.80M 9.22M 8.42M 8.42M 3.73M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income - 0.05M -1.67900M - -1.72500M
Additional paid in capital - - - - -
Common stock total equity - - - - -
Preferred stock total equity - - - - -
Retained earnings total equity - - - - -
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other 3.44M 0.00000M 2.98M 2.98M -
Deferred long term asset charges - - - - -
Non current assets total 8.07M 45.16M 37.10M 37.10M 12.27M
Capital lease obligations 2.44M 7.03M 5.11M 5.11M 1.70M
Long term debt total - - - - -
Breakdown 2024-12-31 2023-12-31 2022-12-31 2022-07-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2024-12-31 2023-12-31 2022-12-31 2022-07-31 2021-12-31
Investments -1.43100M -9.00100M -25.04200M -25.04200M 20.02M
Change to liabilities - - 0.00000M 0.00000M 0.46M
Total cashflows from investing activities -1.43100M - - - 18.70M
Net borrowings -2.55000M - - - -0.29000M
Total cash from financing activities 26.09M -1.29800M 56.90M 56.90M 0.23M
Change to operating activities - - - - -
Net income -29.42700M -24.94700M -39.18900M -39.18900M -26.31600M
Change in cash 1.15M -25.15400M 15.59M 15.59M -1.70300M
Begin period cash flow 16.63M 41.78M 26.19M 26.19M 27.89M
End period cash flow 17.78M 16.63M 41.78M 41.78M 26.19M
Total cash from operating activities -23.59700M -14.87200M -16.43200M -16.43200M -20.50600M
Issuance of capital stock 31.88M 0.40M 9.49M 9.49M 0.52M
Depreciation 1.44M 3.67M 3.01M 3.01M 2.38M
Other cashflows from investing activities -1.10800M - - - -
Dividends paid - - - - -
Change to inventory - 0.20M 0.05M 0.05M 0.01M
Change to account receivables -0.24400M 0.84M 2.23M - -1.59900M
Sale purchase of stock - - - - -
Other cashflows from financing activities -3.23100M -0.24600M 47.42M 47.42M -0.29000M
Change to netincome - - 15.88M 15.88M 4.61M
Capital expenditures 0.34M 1.26M 0.76M 0.76M 1.31M
Change receivables - - - - -
Cash flows other operating - - - - -
Exchange rate changes - - - - -
Cash and cash equivalents changes - - - - -
Change in working capital 0.31M 0.74M 3.87M 3.87M -1.13000M
Stock based compensation 4.11M 2.91M 7.49M 7.49M 5.08M
Other non cash items -0.03400M 12.25M 8.66M 8.38M 0.12M
Free cash flow -23.93600M -16.13400M -17.19100M -17.19100M -21.82000M

Peer Comparison

Sector: Healthcare Industry: Biotechnology

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
AVCTF
Avacta Group Plc		 - -% 1.00 - - 3593.88 2080.04 3156.50 -14.8007
NVO
Novo Nordisk A/S		 0.09 0.19% 47.51 41.58 31.15 2.13 32.99 2.11 4.70
NONOF
Novo Nordisk A/S		 - -% 46.84 41.06 31.25 2.08 33.11 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc		 7.91 1.69% 476.32 29.67 24.33 10.38 5.83 9.33 20.00
REGN
Regeneron Pharmaceuticals Inc		 3.79 0.61% 621.82 29.07 20.12 7.57 3.82 6.95 19.42

Reports Covered

Stock Research & News

View All

Profile

Avacta Group Plc, together with its subsidiaries, engages in the development of cancer therapies in the United Kingdom, South Korea, and internationally. Its lead product candidate is AVA6000, a peptide drug conjugate form of doxorubicin, which is an approved cancer drug with known severe toxicities. The company is developing AVA6103, a peptide drug conjugate technology designed to deliver exatecan, a potent topoisomerase I inhibitor directly to tumors while limiting the exposure of the released exatecan in normal tissues; and AVA7100 that drives localization to fibroblast activation protein expressing tumors. The company was incorporated in 2003 and is headquartered in London, the United Kingdom.

Avacta Group Plc

Scale Space White City Imperial College Campus, London, United Kingdom, W12 7RZ

Key Executives

Name Title Year Born
Dr. David Alastair Smith CEO & Exec. Director NA
Mr. Tony Gardiner CFO, Company Sec. & Exec. Director 1971
Ms. Emma Wright Group In-House Counsel NA
Mr. Michael Vinegrad Group Communications Director NA
Dr. Matt Johnson Chief Scientific Officer of Diagnostics NA
Dr. Neil Bell Chief Devel. Officer of Therapeutics 1958
Dr. Fiona McLaughlin FSB, Ph.D. Chief Scientific Officer of Therapeutics Division 1970
Mr. Marc Green Head of Product Devel. - Diagnostics NA
Gemma Wilson Head of QA/RA - Diagnostics NA
Mr. Petros Sarantos Head of Product Management - Diagnostics NA

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.